Home
BAL PHARMA

BAL PHARMA Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainbalpharma.com

Year Founded1987

Employees501 - 1000

Annual Revenue$25M - $50M

BAL PHARMA

BAL PHARMA (including company regionals)

balpharma.com

See more website traffic and engagement information

BAL PHARMA Revenue up to May 2026 is 25M - 50M

revenue generated by BAL PHARMA top domains

BAL PHARMA top domains revenue over 3 years

Revenue for BAL PHARMA top domains

balpharma.com25M - 50M

See more with Sales Intelligence

Total visits to BAL PHARMA's top domains

Understand BAL PHARMA market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

balpharma.com4.5K

See more with Sales Intelligence

Avg. visit duration in BAL PHARMA's top domains

Analyze BAL PHARMA engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

balpharma.com00:00:09

See more with Sales Intelligence

Avg. pageviews on BAL PHARMA's top domains

See how BAL PHARMA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

balpharma.com1.53

See more with Sales Intelligence

BAL PHARMA top competitors by domain

Top similar sites in May 2026, ranked by their affinity

algorithm-lb.comCompany NameAlgorithmEmployees201 - 500HQLebanon, BeirutAnnual revenue< $1MTotal visits161Health > Biotechnology and Pharmaceuticals

Top technologies used by BAL PHARMA

These are the website technologies, by industry, used by BAL PHARMA top domains

Advertising (1)

PubMatic

Email Services (1)

Amazon SES

Mobile (1)

Meta Viewport

Other (1)

Google API

News & Signals from BAL PHARMA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBal Pharma Limited had earnings of $711K on Jan 1st '26.Bal Pharma reported a 13.4% decline in FY26 net profit to ₹675.12 lakh, while revenue from operations increased 2.7% to ₹31,079.70 lakh.

Newsabdul Basith left Bal Pharma Limited as Company Secretary & Compliance Officer on May 11th '26.Bal Pharma's Company Secretary & Compliance Officer abdul Basith resigns effective May 11, 2026.

NewsBal Pharma Limited launched Sitagliptin (a DPP-4 Inhibitor on Oct 17th '22.New Product Launch in Glyduz division - Bal Pharma has launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively, which recently became off patented.